Regenerative Biologics Supplier for Syracuse, NY Orthopedics

Shipping and cold-chain handling in the Northeast

Cryopreserved Wharton's jelly and exosome products ship overnight on dry ice in validated containers regardless of destination, and Northeast practices should plan receiving around weather-related carrier delays by confirming a staff member will be present to log and transfer the shipment into -80 degree C storage as soon as it arrives.

Practices that prefer to avoid cold-chain receiving windows sometimes stock the lyophilized Wharton's jelly format instead, which is stored at normal conditions per the product insert supplied with the lot.

Documentation an orthopedic group typically requests

Before approving a new vendor, orthopedic practices generally ask for the certificate of analysis for the lot in question, a donor eligibility summary describing the screening process, and confirmation of how lot-level sterility testing and quarantine release are handled. Precision Biologics provides this documentation set to verified accounts on request rather than publishing it broadly.

Some practices also ask how product use is tracked once it reaches the clinic; Precision Biologics recommends logging each product by lot number in the patient record so the lot can be traced if needed.

Setting up an NPI-verified account

Every order is placed through an account tied to a National Provider Identifier, which is checked against the NPPES registry before the account is activated. This confirms the account belongs to a licensed physician or a clinic operating under physician supervision; it is a procurement safeguard, not a clinical evaluation, and Precision Biologics does not weigh in on how a practice intends to use any product.

Confirming licensure with New York's medical board

New York practices should independently verify their own physicians' licensure standing with the New York medical board and consult their own counsel on how state and federal rules apply to their intended use of any product; Precision Biologics does not provide legal or clinical guidance and does not advise on technique or patient selection.

To make account setup straightforward, Precision Biologics verifies the submitted NPI and then releases the donor eligibility summary, certificate of analysis, and lot release record together, so a practice's internal compliance review has a complete file from the outset.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.